Voyager Therapeutics, Inc. (VYGR)

Over the past six months, Voyager Therapeutics' stock has been influenced by financial results, pipeline advancements, and analyst activities. Voyager reported its First Quarter 2026 financial results, including collaboration revenue of $2.6 million and a net loss of $27.9 million. Voyager's IV-delivered CNS gene therapies were featured in multiple presentations at ASGCT 2026. The company held a "BBBreaking BBBarriers: TRACER Platform Deep Dive" event. An analyst report maintained a "Strong Buy" rating. Voyager participated in a "BBBreaking BBBarriers: A NeuroShuttle Deep Dive" event and the Stifel 2026 Virtual CNS Forum. Voyager reported its Fourth Quarter and Full Year 2025 financial results, with a quarterly loss of $27.4 million and revenue of $15.3 million. Voyager presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Voyager participated in the Stifel 2025 Healthcare Conference and reported Q3 2025 earnings with a loss of -$0.470 USD per share. The stock price as of May 1, 2026, was $3.75, with analysts having a median target of $22.00.

The available information does not indicate traditional demand seasonality for Voyager Therapeutics, Inc.'s products and services. Revenue is primarily driven by collaboration agreements and pipeline milestones rather than seasonal fluctuations in product sales. The "demand" for Voyager's offerings is characterized by the progression of its clinical pipeline and the strategic value of its TRACER platform to partners.

Voyager Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe neurological diseases by leveraging human genetics. The company's pipeline includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, and ALS, utilizing its TRACER AAV capsid discovery platform. Key programs include VY1706 for Alzheimer's disease, VY7523, research programs for Huntington's disease, SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, ALPL-VYGR-NeuroShuttle, and development of selective small molecules for ALS and frontotemporal dementia. Voyager collaborates with companies like Alexion, AstraZeneca, Novartis, and Neurocrine Biosciences.

Voyager Therapeutics is headquartered in Lexington, Massachusetts, United States. While its primary operations are in Massachusetts, collaborations with international pharmaceutical entities suggest a broader global reach. Expanding its presence outside the United States would require additional resources to comply with international laws.

Voyager Therapeutics' brand reputation is tied to its scientific advancements, pipeline progress, and financial performance. Positive perception stems from its TRACER platform and preclinical results, but setbacks in gene therapy programs and rising operational costs raise concerns. Positive clinical data and pipeline updates, presentations at scientific conferences, financial results indicating cost control, and generally positive analyst ratings have impacted its reputation.

Voyager Therapeutics has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors hold approximately 10.99% to 48.03% of the company's stock. Insiders hold approximately 2.21% to 6.39% of the stock, and have sold more company stock than they have bought in the past three months. Retail investors hold a significant portion, approximately 77.50% of the stock.